The week in pharma: action, reaction and insight – week to September 2

By Barbara Obstoj-Cardwell. Managing editor

Important research news last week included Germany’s Bayer and US drug major Bristol Myers Squibb releasing new data at the European Society of Oncology (ESC) on their asundexian and milvexian, respectively. On the M&A front, last Tuesday Diurnal said it has agreed to an acquisition by US neurology specialist Neurocrine Biosciences, then on Thursday, Danish diabetes care giant Novo Nordisk announced a $1.1 billion deal to acquire Forma Therapeutics and its sickle cell disease drug candidate etavopivat. Also of note, Denmark’s Ascendis Pharma last week said it has filed for US Food and Drug Administration (FDA) approval for its hypoparathyroidism candidate TransCon PTH.

Bullish FXIa inhibitor KOL call takeaways